Signal transducer and activator of transcription 3 (STAT3) signaling pathways have been suggested to play a key role in tumorigenesis, progression, and drug resistance in several human malignancies, including leukemia, lymphomas, hepatocellular carcinoma, and esophageal, lung, prostate, bladder, and breast cancers [9,10]. This evidence concerns the gene STAT3 and hepatocellular carcinoma.